Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
21 Results for "
Staphylococcus aureus topoisomerase IV
" in MedChemExpress (MCE) Product Catalog:
Products (21)
21 Results for "Staphylococcus aureus topoisomerase IV" in MCE Product Catalog:
1
Research Areas:
Nadifloxacin (OPC7251) is a broad-spectrum quinolone antibiotic. Nadifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, interfering with DNA replication. It also suppresses the production of proinflammatory cytokines (such as IL-1α, IL-6, and IL-8). Nadifloxacin exhibits antibacterial activity against various pathogens, including Propionibacterium acnes and Staphylococcus aureus. Nadifloxacin also exhibits anti-inflammatory activity. Nadifloxacin can be used in the research of skin infections such as acne vulgaris, folliculitis, and impetigo .
Cat. No.: HY-U00035
CAS No.: 1000277-08-6
Target:
Research Areas:
MGB-BP-3 is an orally aective Gram-positive bactericide and DNA-binding agent. MGB-BP-3 blocks transcription initiation by binding to AT-rich bacterial DNA regions, and interferes with the functions of DNA gyrase and topoisomerase IV, but does not stabilize cleavage complexes or induce the SOS response. MGB-BP-3 induces energy depletion in *Staphylococcus aureus* and inhibits spore formation in *Clostridioides difficile*, exhibiting intrinsic resistance resilience. MGB-BP-3 can be used in the research of *Clostridioides difficile*-associated diseases .
Cat. No.: HY-108988
CAS No.: 1622253-00-2
Research Areas:
Albicidin is a peptide antibiotic with phytotoxic activity. Albicidin potently inhibits bacterial and plant DNA gyrase at nanomolar concentrations, blocks DNA replication, and exhibits excellent antibacterial efficacy against multidrug-resistant bacteria. Albicidin possesses bactericidal activity against Gram-positive and Gram-negative microorganisms, and acts as a virulence factor for the systemic plant infection by Xanthomonas albilineans. Albicidin can be used in studies related to bacterial infections and sugarcane leaf blight .
Cat. No.: HY-E70899A
Target:
Research Areas:
Topoisomerase IV, Staphylococcus aureus (EC 5.99.1.) is prepared by overexpressing the subunits in E.coli.
Cat. No.: HY-135184
CAS No.: 922717-97-3
Synonyms: CBR-2092; TNP-2092
Target:
Research Areas:
Rifaquizinone (CBR-2092; TNP-2092) is a rifamycin-quinolone hybrid antibiotic. Rifaquizinone has an IC50 of 0.034 μM against wild-type Staphylococcus aureus DNA-dependent RNA polymerase. Rifaquizinone potently inhibits Staphylococcus aureus infection, with an MIC range of 0.008-0.5 μg/mL against 300 clinical isolates of staphylococci and streptococci. Rifaquizinone can be used in research related to persistent Staphylococcus aureus infections .
Cat. No.: HY-115990
CAS No.: 2883403-42-5
Target:
Research Areas:
Topoisomerase IV inhibitor 2 (compound 7d) is a potent DNA topoisomerase IV (TOPO IV) inhibitor with IC50s of 0.23 μM and 0.43 μM for TOPO IV and DNA gyrase, respectively. Topoisomerase IV inhibitor 2 has anti-bacterial activity, with MICs of 0.972 μM and 0.608 μM in Staphylococcus aureus Newman and Escherichia coli ATCC8739, respectively .
Cat. No.: HY-170567
CAS No.: 3087956-87-1
Target:
Research Areas:
DNA gyrase/Topo IV-IN-1 (Compound 27) is an inhibitor of DNA gyrase and topoisomerase IV, exhibiting antibacterial activity. For Escherichia coli and methicillin-resistant Staphylococcus aureus DNA gyrases, DNA gyrase/Topo IV-IN-1 has an IC50 of 11 and 17 nM respectively, and for topoisomerase IV of Escherichia coli and methicillin-resistant Staphylococcus aureus, the IC50 values are 83 and 21 nM respectively. DNA gyrase/Topo IV-IN-1 can be used for research in the field of anti-infection .
Cat. No.: HY-115991
CAS No.: 2883403-36-7
Target:
Research Areas:
Topoisomerase IV inhibitor 2 (compound 5d) is a potent DNA topoisomerase IV (TOPO IV) inhibitor with IC50s of 0.35 μM and 0.55 μM for TOPO IV and DNA gyrase, respectively. Topoisomerase IV inhibitor 2 has anti-bacterial activity, with MICs of 1.985 μM and 0.744 μM in Staphylococcus aureus Newman and Escherichia coli ATCC8739, respectively .
Cat. No.: HY-184297
Target:
Research Areas:
Topoisomerase II-IN-26 is a dual bacterial type II topoisomerase (Top II) inhibitor, with IC50 values of 0.081 μM and 0.093 μM against Staphylococcus aureus DNA gyrase and topoisomerase IV, respectively, and IC50 values of 0.906 μM and 0.103 μM against Escherichia coli DNA gyrase and topoisomerase IV, respectively. Topoisomerase II-IN-26 also shows high selectivity for human topoisomerase IIα. Topoisomerase II-IN-26 inhibits biofilm formation, reduces the metabolic activity of mature biofilms, exhibits activity against Staphylococcus aureus, MRSA strains, Escherichia coli and Acinetobacter baumannii, and possesses a post-antibiotic effect. Topoisomerase II-IN-26 can be used for the research of bacterial infections such as Staphylococcus aureus and MRSA .
Cat. No.: HY-14780
CAS No.: 904302-98-3
Synonyms: NXL 101
Research Areas:
Viquidacin (NXL 101) is an antibiotic with inhibitory activity against topoisomerase IV and DNA gyrase. Viquidacin exhibits antibacterial activity against gram positive bacterial by inhibiting the supercoiling, decatenation and relaxation in strains Staphylococcus aureus and Escherichia coli in micromolar levels. Viquidacin inhibits S. aureus wildtype and mutants with MIC of 2-128 mg/L .
Cat. No.: HY-161937
CAS No.: 2364479-10-5
Target:
Research Areas:
Antibacterial agent 236 (Compound 4l) is an orally active inhibitor for DNA gyrase and topoisomerase IV (IC50 is 3.2 and 300 nM in Staphylococcus aureus), and exhibits board-spectrum antibacterial activity. Antibacterial agent 236 exhibits good pharmacokinetic properties in mice .
Cat. No.: HY-189061
Target:
Research Areas:
Topoisomerase IN-7 is a bacterial topoisomerase inhibitor, with an IC50 value of 47 nM against Staphylococcus aureus DNA gyrase, 85 nM against Escherichia coli DNA gyrase, and 1 nM against Escherichia coli topoisomerase IV. Topoisomerase IN-7 inhibits the supercoiling activity of DNA gyrase, suppresses the relaxation activity of topoisomerase IV, stabilizes single-stranded DNA cleavage complexes, inhibits biofilm formation of specific bacteria, stimulates biofilm formation of methicillin-resistant Staphylococcus aureus, and exhibits bactericidal activity. Topoisomerase IN-7 is selective for bacterial topoisomerases over human topoisomerase IIα, shows moderate cytotoxicity, and inhibits the hERG potassium channel. Topoisomerase IN-7 can be used in studies of bacterial infections .
Cat. No.: HY-181820
Target:
Research Areas:
Topoisomerase IV-IN-3 is a Staphylococcus aureus Topoisomerase IV inhibitor, DNA gyrase inhibitor and antibacterial agent. Topoisomerase IV-IN-3 has IC50 values of 1.32 μM and 0.48 μM against topoisomerase IV, and 0.88 μM and 0.54 μM against DNA gyrase. Topoisomerase IV-IN-3 inhibits decatenation, ATPase, and supercoiling activities of its target enzymes. Topoisomerase IV-IN-3 exerts antibacterial activity against Gram-positive and Gram-negative bacterial strains. Topoisomerase IV-IN-3 exhibits low cytotoxicity toward human fibroblast cells. Topoisomerase IV-IN-3 can be used for the research of bacterial infections .
Cat. No.: HY-181819
CAS No.: 1311163-39-9
Target:
Research Areas:
Antibacterial agent 327 (Compound 6f) is an Antibacterial agent. Antibacterial agent 327 potently inhibits the supercoiling activity of Staphylococcus aureus DNA gyrase with an IC50 of 0.28 μM. It also inhibits the ATPase activities of DNA gyrase and Topoisomerase IV, as well as the decatenation activity of Topoisomerase IV (IC50: 0.43 μM, 0.73 μM, and 2.31 μM, respectively). Antibacterial agent 327 potently inhibits Clostridioides difficile and methicillin-resistant Staphylococcus aureus (HY-121544), with an MIC of 0.78 μg/mL for both. Antibacterial agent 327 inhibits Escherichia coli with an MIC50 of 0.78 μg/mL .
Cat. No.: HY-113718
CAS No.: 1037366-37-2
Target:
Research Areas:
DS21412020 is a fluoroquinolone antibacterial agent. DS21412020 inhibits bacterial DNA gyrase (GyrA) and topoisomerase IV, leading to DNA breaks. DS21412020 exhibits significant activity against Gram-positive bacteria such as Staphylococcus aureus (MIC = 0.006 μg/mL), Streptococcus pneumoniae (MIC = 0.05 μg/mL), and Methicillin (HY-121544)-resistant Staphylococcus aureus (MIC = 0.2 μg/mL), and Gram-negative bacteria such as Escherichia coli (MIC = 0.006 μg/mL) and Pseudomonas aeruginosa (MIC = 0.78 μg/mL). DS21412020 significantly reduces bacterial load in mouse pneumonia and MRSA infection models. DS21412020 can be used in the development of next-generation quinolone antibiotics .
Cat. No.: HY-180414
CAS No.: 143383-65-7
Target:
Research Areas:
Premafloxacin is a potent antimicrobial agent that exhibits activity against Staphylococcus aureus, Corynebacterium bovis, and Corynebacterium amylocolatum. Premafloxacin demonstrated potent antimicrobial activity against S. aureus by targeting topoisomerase IV, and is a poor substrate for NorA efflux pump. Premafloxacin can be used for antimicrobial research .
Cat. No.: HY-B0395E
CAS No.: 127254-11-9
Synonyms: (1S,2R,7S)-DU-6859a; DU-6856
Target:
Research Areas:
(1S,2R,7S)-Sitafloxacin (DU-6856) is an enantiomer of Sitafloxacin (HY-B0395). (1S,2R,7S)-Sitafloxacin is a topoisomerase inhibitor. (1S,2R,7S)-Sitafloxacin is an antibiotic. (1S,2R,7S)-Sitafloxacin has inhibitory activity against Escherichia coli DNA gyrase (IC50 0.18 μg/mL) and Staphylococcus aureus topoisomerase IV. (1S,2R,7S)-Sitafloxacin has antibacterial activity and can be used in the study of various bacterial infections .
Cat. No.: HY-B0506R
CAS No.: 124858-35-1
Synonyms: OPC7251 (Standard)
Research Areas:
Nadifloxacin (Standard) is the analytical standard of Nadifloxacin (HY-B0506). This product is intended for research and analytical applications. Nadifloxacin (OPC7251) is a broad-spectrum quinolone antibiotic. Nadifloxacin inhibits bacterial DNA gyrase and topoisomerase IV, interfering with DNA replication. It also suppresses the production of proinflammatory cytokines (such as IL-1α, IL-6, and IL-8). Nadifloxacin exhibits antibacterial activity against various pathogens, including Propionibacterium acnes and Staphylococcus aureus. Nadifloxacin also exhibits anti-inflammatory activity. Nadifloxacin can be used in the research of skin infections such as acne vulgaris, folliculitis, and impetigo .
Cat. No.: HY-B0506S1
Synonyms: OPC7251-d5
Cat. No.: HY-189127
CAS No.: 668468-75-5
Antibacterial agent 373 is a broad-spectrum antibacterial agent. Antibacterial agent 373 exhibits antibacterial activity against Gram-negative/Gram-positive bacteria and some fungi, with MIC values ranging from 11.25 to 22.5 mg/mL. Antibacterial agent 373 is predicted to target Staphylococcus aureus topoisomerase IV, occupy the novobiocin binding pocket, and form hydrogen bonds with the active site residues Asn49 and Glu53. Antibacterial agent 373 can be used in studies related to bacterial and Candida infections .
- 1
- 2
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
